Given that DYRK1A is not the only target gene regulated by KMT2A, we specifically focused on studying the importance of DYRK1A for KMT2A-R ALL survival using DYRK1A inhibitors. This evidence concerns the gene DYRK1A and acute lymphoblastic leukemia.